RE:ManagementJP, a conference call is scheduled for the 12th to go along with the finacial update. with no revenue stream, the prospect of an expensive redo of the PIII trial, and a substancial cash burn, the only catalyst that would drive the price up in a signifacant way would be a buyout, or European approval.